Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05661734 · ClinicalTrials.gov registry record · Phase 3
A Single-arm Study to Evaluate Safety and Effectiveness of VX-548 for Acute Pain
A Phase 3 study, sponsored by Vertex Pharmaceuticals Incorporated.
- Completed
- Registry status
- Phase 3
- Development phase
- 258
- Enrollment target
NCT05661734: Completed Phase 3 study, sponsored by Vertex Pharmaceuticals Incorporated.
NCT05661734 is a Phase 3 study that has completed, run by Vertex Pharmaceuticals Incorporated. The registered enrollment target is 258 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (67% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05661734, a Phase 3 study, has completed, sponsored by Vertex Pharmaceuticals Incorporated.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 258 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and effectiveness of VX-548 in treating acute pain.
Interventions
- DRUG Suzetrigine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 258 participants |
| Start Date | 2023-01-09 |
| Est. Completion | 2023-12-12 |
| Phase | Phase 3 |
What the finished NCT05661734 record still lists
NCT05661734 is an interventional study that assigns participants to a tested intervention. The registered 258 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (67% lower).
The record links to 0 conditions, and to 1 intervention - of which Suzetrigine is the first listed.
NCT05661734 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05661734 about?
NCT05661734 is a clinical study titled "A Single-arm Study to Evaluate Safety and Effectiveness of VX-548 for Acute Pain". The purpose of this study is to evaluate the safety and effectiveness of VX-548 in treating acute pain.
What is the current status of trial NCT05661734?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 258 participants. The study started on 2023-01-09. Estimated completion is 2023-12-12.
What interventions are being tested in trial NCT05661734?
The interventions under investigation include: Suzetrigine (DRUG).
Who is sponsoring clinical trial NCT05661734?
This trial is sponsored by Vertex Pharmaceuticals Incorporated, which has 191 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05661734's enrollment target sits among peer trials
258 1235th of 2000 higher than 763 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03785288 · 258 participants · Phase 3
Vaginal Cuff Brachytherapy Fractionation Study
- NCT04643002 · 258 participants · Phase 1
Isatuximab in Combination With Novel Agents in RRMM - Master Protocol
- NCT04924322 · 258 participants · Phase 2
Catheter-Related Early Thromboprophylaxis With Enoxaparin Studies
- NCT05043012 · 258 participants · NA
Diagnostic Performance Of Non-Endorectal Coil Multiparametric Magnetic Resonance Imaging Of Prostate With Flexible AIR Coil (DoNEMAC Study)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI